Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics, Inc. (Nasdaq: SPRO) submitted an NDA to the U.S. FDA for its oral antibiotic, tebipenem HBr, targeting complicated urinary tract infections (cUTI), with a potential launch in H2 2022. Additionally, the company entered a non-dilutive revenue financing agreement with HealthCare Royalty Partners for up to $125 million, enhancing its financial position. The third-quarter report shows a net loss of $22.5 million, down from $18.9 million the prior year, with total revenues at $3.1 million. Despite these challenges, Spero's cash reserves of $123.4 million should sustain operations into Q4 2022.
Spero Therapeutics, Inc. (Nasdaq: SPRO) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide updates on its business and pipeline. The company focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero's lead candidate, tebipenem HBr, is under review with a new drug application filed after positive Phase 3 trial results. Other developments include an oral therapy for NTM infections and an IV-administered polymyxin product for treating MDR infections.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the submission of a New Drug Application (NDA) to the FDA for tebipenem HBr tablets, aimed at treating complicated urinary tract infections (cUTI). This marks a significant advancement as tebipenem HBr would be the first oral carbapenem antibiotic for cUTI if approved. Data from the Phase 3 ADAPT-PO trial confirmed its effectiveness, showing non-inferiority to IV ertapenem. The anticipated launch is set for the second half of 2022, which could reduce healthcare resource utilization by shifting from IV to oral treatments.
Spero Therapeutics (Nasdaq: SPRO) has appointed Kathleen Tregoning to its Board of Directors, effective October 12, 2021. Tregoning, a seasoned biotechnology executive, replaces Jean-François Formela, who resigned as part of a planned transition. Currently the Chief Corporate Affairs Officer at Cerevel Therapeutics, Tregoning's extensive experience in public policy and corporate affairs is expected to greatly benefit Spero, especially as it prepares for the anticipated launch of tebipenem HBr and other clinical programs. Spero focuses on developing treatments for multi-drug resistant infections and rare diseases.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the grant of non-qualified stock options for 12,900 shares to three new employees under the 2019 Inducement Equity Incentive Plan. This move, made on September 30, 2021, is intended to attract new talent as per Nasdaq rules. Each option has an exercise price of $18.41 and will vest over four years, contingent upon the employees' continued employment. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, with notable products like tebipenem HBr and SPR720.
Spero Therapeutics (Nasdaq: SPRO) announced a $125 million revenue interest financing with HealthCare Royalty Partners to enhance its cash runway into 2H 2023. The company will receive $50 million by October 21, 2021, with potential additional funds tied to FDA approval of its lead product, tebipenem HBr, for complicated urinary tract infections. The agreement will provide tiered royalties on revenues generated by tebipenem HBr and its other products. This strategic partnership aims to support Spero's clinical development and launch plans.
Spero Therapeutics (Nasdaq: SPRO) announced 23 data presentations at the IDWeek 2021, occurring virtually from September 29 to October 3, 2021. The presentations will focus on the in vitro and in vivo studies related to tebipenem HBr, an investigational oral antibiotic aimed at treating complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). Notably, Spero's tebipenem HBr was highlighted for its potential as the first oral carbapenem antibiotic specifically for these conditions.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that Ankit Mahadevia, M.D., CEO, will present at three upcoming virtual conferences: H.C. Wainwright 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Cantor Virtual Global Healthcare Conference (Sept 27-30). Webcasts of these presentations will be available on-demand. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, notably its lead product candidate, tebipenem HBr.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the grant of non-qualified stock options to purchase 98,300 shares of common stock to 7 new employees on August 31, 2021. This was conducted under the 2019 Inducement Equity Incentive Plan, as per Nasdaq's Rule 5635(c)(4). The options have an exercise price of $19.25, the same as the closing price on that date, and will vest over four years. Spero is focused on treatments for multi-drug-resistant infections and rare diseases, with notable candidates like tebipenem HBr for urinary tract infections and SPR720 for rare pulmonary diseases.
Spero Therapeutics announced notable developments including plans to submit an NDA for tebipenem HBr in Q4 2021 and a $40 million equity investment from Pfizer. The investment supports the licensing agreement for SPR206, aimed at treating multi-drug resistant infections. Despite a net loss of $18.6 million for Q2 2021, total revenues increased to $5.1 million, reflecting grants and collaborations. The company reported cash reserves of $99.2 million, expected to sustain operations into late 2022.
